Devyser Chimerism NGS

About Devyser

Devyser's mission is to make personalized healthcare universally accessible by providing diagnostic labs with simplified, robust, and integrated genetic testing solutions. Since its founding in 2004, the company has established a strong portfolio of CE-IVD and RUO NGS kits, achieving a global footprint in over 45 countries. Its strategy focuses on deepening its presence in core verticals like transplantation and oncology through product innovation, strategic acquisitions (e.g., Cybergene), and partnerships (e.g., Illumina supply agreement), while navigating the regulatory pathway for key market entries, including the US.

Therapeutic Areas